Announcement of Stock Awards for Employees
Company Announcement
COPENHAGEN, Denmark – Genmab A/S (NASDAQ: GMAB) has declared the decision by its Board of Directors to award a total of 6,933 restricted stock units along with 7,377 warrants to the employees of Genmab and its subsidiaries.
These restricted stock units are issued at no cost to workers, granting them the potential to receive a single share in Genmab A/S, nominally valued at DKK 1. The market value of each unit corresponds to the share's closing price on the grant date, which stands at DKK 1,957.
The vesting of restricted stock units is set to occur on the first banking day after a three-year period commencing from the grant date. Additionally, these units come with specific vesting qualifications defined in the company’s stock unit program, which is documented in detail.
The warrants, likewise awarded at no cost, hold an exercise price of DKK 1,957, allowing holders to subscribe to one share of nominal DKK 1, contingent on paying the exercise price. Using the Black-Scholes model, the value of each warrant is established at DKK 612.85.
As for the warrants, they will also become effective three years from the grant date, and they expire upon reaching the seventh anniversary of the signing date. These newly granted warrants adhere to the established terms set by the warrant program instituted by the Board of Directors in February 2021.
Understanding Genmab’s Employee Incentives
The issuance of restricted stock units and warrants points towards Genmab’s commitment to fostering employee motivation and retention. By tying employee rewards to the performance of Genmab’s stock, the company encourages its staff to invest in the organization’s long-term success.
With a primary focus on groundbreaking antibody therapeutics, Genmab aims to improve patient lives significantly. Their dedication has led to invaluable innovations, targeting conditions such as cancer and other severe illnesses, reinforcing the company's mission.
Strategic Goals for 2030
Genmab aims for a future where its advanced antibody medicines, under the tagline “knock-your-socks-off (KYSO)”, revolutionize treatment methods by the year 2030. This vision reflects a commitment to harnessing state-of-the-art technology and scientific research toward life-changing medical solutions.
The company, established in 1999 in Copenhagen, Denmark, extends its innovative research and development efforts on a global scale, including notable operations in North America, Europe, and Asia Pacific.
Overview of Company Operations
Genmab has built a respected reputation in biopharmaceutical development, cultivating an extensive pipeline that includes next-generation antibody technology platforms, bispecific T-cell engagers, and antibody-drug conjugates. Their teams operate collaboratively, driven by a shared purpose of patient-centric innovation.
For updates on Genmab’s journey and future projects, interested parties can visit their official website, engaging with more news about their breakthroughs.
Connecting with Genmab
Staying connected with Genmab can provide investors, partners, and patients with the latest developments in biotechnology. There are various avenues to seek out this information, including newsletters, press releases, and social media presence.
With dedicated sections for investor information and corporate governance, the company ensures transparency and accessibility to crucial data for stakeholders.
Contact Information
For further inquiries about Genmab's strategic direction and operations, individuals can contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
Frequently Asked Questions
What are restricted stock units?
Restricted stock units are a form of compensation where the employee earns shares after fulfilling certain conditions such as time-based vesting.
What does the exercise price of a warrant indicate?
The exercise price is the amount required to purchase shares when executing the warrant, which for Genmab is set at DKK 1,957 per share.
How does Genmab support its employees?
Genmab supports its employees through initiatives like stock awards, aiming to motivate and retain talent by aligning employee success with company success.
What is Genmab’s primary focus?
Genmab focuses on developing innovative antibody therapeutics that improve patient outcomes, specifically targeting cancer and other serious diseases.
Where can I find more information about Genmab?
More information can be found on Genmab's official website, which includes details on governance, investor relations, and recent announcements.
